MVA member Genmab ranked among Europe’s Brightest Stars: The 9 Best Biotech Companies of 2017

    “Since its foundation in 1999, the Copenhagen-based company has been developing antibody-based therapies to treat cancer. Now, it is Europe’s perhaps most fiercely independent biotech, though word on the street is that J&J is considering a buyout after the success of Darzalex”, European Biotech editor, Evelyn Warner, from Berlin based,, writes, motivating why Genmab belongs on the list.  

    Read full Labiotech ranking list here.